📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 18:03
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
43 announcements match the current filters (relevance ≥ 5).
13% Revenue Growth and 19.4% EBITDA Margin in Q1 FY27; 800+ Bed Expansion Planned
HCG reported a strong start to FY27 with Q1 revenue growing 13% YoY to ₹695.1 cr, driven by an 11% increase in patient volumes. Adjusted EBITDA grew 20% YoY to ₹133.9 cr, with margins expanding 120 bps to 19.4% due to a favorable shift in payor mix (non-institutional at 69%). The newly commissioned North Bangalore hospital contributed ₹6.7 cr in its first quarter since May 2026. Management has guided for EBITDA margins to reach 21-22% within two years and 25% in 4-5 years, supported by a pipeline of 815+ beds through FY30.
Confidence: HIGH
What changedHCG has transitioned from a consolidation phase (divesting fertility business, rights issue) to an execution phase with the launch of the North Bangalore hospital and a clear multi-year bed expansion roadmap.
Why it mattersThe company is successfully driving operating leverage, with EBITDA growth (20%) significantly outpacing revenue growth (13%), while focusing on high-margin oncology cases and non-institutional payors.
Q1 Revenue: ₹695.1 crAdjusted EBITDA Margin: 19.4%North Bangalore Q1 Revenue: ₹6.7 crPlanned Bed Additions (FY27-FY30): 815 unitsNon-Institutional Payor Mix: 69%Marketing Spend as % of Sales: 2.9%
📅 Short termThe stock may react positively to the margin expansion and the successful initial ramp-up of the North Bangalore unit, which is a key strategic asset.
📈 Long termStructural growth is supported by a ~32% planned increase in bed capacity and a target to reach 25% EBITDA margins through better case mix and operating leverage.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk of large-scale bed expansion
- Regulatory price caps on oncology procedures affecting institutional segments
- High P/E ratio of 769.5 requiring sustained high growth to justify valuation
Key Highlights
Revenue grew 13% YoY to ₹695.1 cr, with 16 out of 25 centers delivering record quarterly revenues.
Adjusted EBITDA margin improved to 19.4% from 18.2% YoY, reflecting strong operating leverage.
North Bangalore hospital recorded 550+ new patient registrations and 300+ admissions in its first quarter.
Aggressive expansion roadmap outlined with 520 beds to be added across FY28 and FY29.
Non-institutional business revenue grew 17% YoY, now contributing 69% of total revenue versus 67% last year.
👀 What to Watch
Monitor the ramp-up of the North Bangalore facility and the execution timeline for the 520-bed expansion planned for FY28-29. Watch for continued improvement in the payor mix toward cash and TPA patients to validate the 21-22% medium-term margin guidance.
HCG Q1 FY27: Revenue up 13% to ₹695 Cr, Adjusted PAT surges 190% YoY
HCG reported a strong start to FY27 with consolidated revenue growing 13% YoY to ₹695.1 Cr, driven by 11% volume growth. Adjusted EBITDA rose 20% to ₹133.9 Cr, with margins expanding 121 bps to 19.4% due to a better payor mix, with non-institutional share rising to 69%. The company commissioned a new 120-bed facility in North Bangalore and added a total of 121 operational beds across its network during the quarter. While Adjusted PAT grew 190% YoY to ₹13.8 Cr, it remains a small fraction of the ₹16,620 Cr market cap, reflecting the high P/E valuation.
Confidence: HIGH
What changedHCG has commissioned its new flagship North Bangalore hospital and divested its fertility business, shifting focus entirely to its core oncology network while achieving double-digit volume growth.
Why it mattersThe expansion and improved payor mix (higher non-institutional share) are key to HCG's strategy of moving centers into higher margin buckets (25%+), which is critical given the company's high valuation multiples.
Q1 FY27 Revenue: ₹695.1 CrAdjusted EBITDA Margin: 19.4%New Beds Added: 121 unitsNon-institutional Revenue Share: 69%Adjusted PAT: ₹13.8 CrRevenue vs TTM Revenue: 27.3%
📅 Short termThe stock may react positively to the 121 bps margin expansion and strong 11% volume growth, though the sequential PAT decline might temper enthusiasm.
📈 Long termStructural growth is supported by the commissioning of advanced facilities like the North Bangalore center and robotic surgery upgrades, though high debt (₹1,022 Cr) and high P/E remain long-term monitoring points.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High P/E ratio of 729.6
- Debt of ₹1,022 Cr relative to ₹1,604 Cr net worth
- Regulatory risks regarding procedure pricing caps
Key Highlights
Revenue grew 13% YoY to ₹695.1 Cr, accounting for approximately 27% of TTM revenue.
Adjusted EBITDA margin improved by 121 bps YoY to 19.4% in Q1 FY27.
Added 121 operational beds during the quarter, including 56 beds at the new North Bangalore facility.
Non-institutional revenue contribution increased from 67% to 69% YoY, improving revenue quality.
Adjusted PAT increased 190% YoY to ₹13.8 Cr, though it declined sequentially from Q4 FY26.
👀 What to Watch
Monitor the ramp-up and insurance empanelment progress at the new North Bangalore facility, and observe if the divestment of the fertility business (Milann) leads to sustained margin improvement in the core oncology segment.
HCG Q1 FY27: 190% YoY PAT Growth to ₹13.8 Cr; Revenue Up 13% to ₹695.1 Cr
HCG reported a strong start to FY27 with revenue growing 13% YoY to ₹695.1 Cr, primarily driven by an 11% increase in patient volumes. Profit After Tax (PAT) saw a significant surge of 190% YoY to ₹13.8 Cr, reflecting high operating leverage. Adjusted EBITDA margins improved to 19.4% from 18.2% in the previous year, aided by a better payor mix with non-institutional patients now comprising 69% of the total. The company also completed its strategic exit from the Milann fertility business in June 2026 to focus exclusively on core oncology.
Confidence: HIGH
What changedHCG reported its Q1 FY27 financial results and confirmed the completion of its divestment from the Milann fertility business.
Why it mattersThe sharp increase in PAT and margin expansion demonstrates the company's ability to scale profitably as it focuses on high-margin oncology treatments and reduces its dependence on lower-margin institutional schemes.
Q1 Revenue: ₹695.1 CrQ1 PAT: ₹13.8 CrAdjusted EBITDA Margin: 19.4%Volume Growth: 11% YoYQ1 Revenue vs TTM Revenue: 27.3%Beds Added: 120+
📅 Short termThe stock is likely to react positively to the 190% PAT growth and margin improvement, reflecting strong operational performance.
📈 Long termThe strategic focus on core oncology, divestment of non-core assets, and brownfield expansions in high-potential clusters position the company for sustainable long-term value creation.
⚠ Risk flags
- Regulatory pricing interventions on oncology drugs
- Integration risks of recent acquisitions in Vizag and Indore
Key Highlights
Revenue grew 13% YoY to ₹6,951 Mn (₹695.1 Cr) led by 11% volume growth.
Adjusted EBITDA increased 20% YoY to ₹1,339 Mn with margins expanding to 19.4%.
Profit After Tax (PAT) surged 190% YoY to ₹138 Mn (₹13.8 Cr).
Added 120+ beds in North Bengaluru in May 2026, strengthening the Bengaluru cluster.
Non-Institutional payor mix improved by 189 bps YoY to reach 69%.
👀 What to Watch
Watch the occupancy ramp-up at the new North Bengaluru facility and the execution of the strategy to migrate 11 centers into the higher-margin >₹100 Mn monthly revenue bucket.
HCG Q1 FY27 Net Profit Surges 190% to ₹13.77 Cr; Completes ₹37.64 Cr Milann Divestment
HCG reported a strong start to FY27 with consolidated total income rising 14.1% YoY to ₹707.23 Cr. Net profit attributable to shareholders jumped to ₹13.77 Cr from ₹4.75 Cr in the year-ago period, representing a 190% increase. The company successfully completed the divestment of its fertility business (Milann) for ₹37.64 Cr on June 29, 2026, to focus on its core oncology operations. Additionally, the board approved a fresh investment of ₹16 Cr in its Rajkot subsidiary.
Confidence: HIGH
What changedHCG has officially exited its non-core fertility business (Milann) and demonstrated a sharp recovery in bottom-line profitability for its core oncology operations.
Why it mattersThe divestment streamlines HCG into a pure-play oncology provider, where it holds a dominant market position with 38 LINAC units. The profit growth indicates improving operational leverage across its hospital network.
Consolidated Revenue (Q1 FY27): ₹707.23 CrNet Profit Attributable (Q1 FY27): ₹13.77 CrMilann Divestment Value: ₹37.64 CrRajkot Subsidiary Investment: ₹16 CrYoY Revenue Growth: 14.1%
📅 Short termThe stock is likely to react positively to the significant profit growth and the strategic clarity provided by the completion of the Milann divestment.
📈 Long termStructural focus on oncology and the strategy to scale Tier 2 centers into higher margin buckets support the company's long-term growth target of 18%.
⚠ Risk flags
- High P/E ratio (729.6) implies high growth expectations
- Divestment was to a related party (Inviga Healthcare Fund I)
- Regulatory price caps on oncology procedures
Key Highlights
Consolidated Total Income grew 14.1% YoY to ₹707.23 Cr from ₹619.99 Cr.
Net Profit attributable to equity holders surged 190% YoY to ₹13.77 Cr.
Completed divestment of BACC Healthcare (Milann) for ₹37.64 Cr on June 29, 2026.
Board approved additional investment of up to ₹16 Cr in HCG Rajkot Hospitals LLP.
Consolidated Basic EPS improved significantly to ₹0.92 from ₹0.34 YoY.
👀 What to Watch
Monitor the margin trajectory as the company integrates recent acquisitions in Vizag and Indore and aims to move 11 centers into higher revenue buckets (>₹10 Cr monthly). Watch for the impact of the new ESOP scheme on employee benefit expenses in upcoming quarters.
HCG Shareholders Approve 2026 ESOP Scheme and CEO Pay Revision Despite Institutional Dissent
HCG shareholders have approved five special resolutions via postal ballot, including the launch of the HCG Employee Stock Option Scheme – 2026 and a revision in the remuneration for CEO Dr. Manish Mattoo. While all resolutions passed with the requisite majority, there was significant institutional resistance, with approximately 61% of institutional votes cast against the ESOP scheme and the CEO's pay revision. The promoter group, holding 64.2% of the company, voted 100% in favor, ensuring the passage of these special resolutions. Total voter turnout was high at 83.54% of the total share capital.
Confidence: HIGH
What changedThe company has formally adopted a new 2026 ESOP scheme and updated the compensation structure for its Executive Director and CEO.
Why it mattersWhile ESOPs are essential for talent retention in the healthcare sector, the high level of institutional dissent indicates a potential misalignment between the board and public institutions regarding compensation and dilution levels.
Total shares held: 14,93,02,203Institutional dissent on ESOP: 61.01%Institutional dissent on CEO pay: 60.85%Promoter voting in favor: 100%Total votes polled: 12,47,29,999
📅 Short termThe stock is unlikely to see significant movement based on this administrative result, as the resolutions were successfully passed.
📈 Long termThe new ESOP scheme will lead to gradual equity dilution over the coming years; persistent institutional friction on governance matters could impact future ESG ratings or institutional inflows.
⚠ Risk flags
- High institutional dissent on compensation
- Potential equity dilution from new ESOP scheme
Key Highlights
All 5 special resolutions passed with overall favorable votes ranging from 85.9% to 92.3%
Institutional investors showed high dissent, with 61.01% of institutional votes cast against the 2026 ESOP Scheme
Revision of CEO Dr. Manish Mattoo's remuneration saw 60.85% of institutional votes cast against the proposal
The promoter group (9.58 crore shares) voted 100% in favor of all resolutions, providing the necessary weight for passage
Total voter turnout represented 83.54% of the 14.93 crore total shares outstanding
👀 What to Watch
Investors should monitor the specific terms of the 2026 ESOP scheme for potential equity dilution and observe if the high institutional dissent leads to changes in the board's approach to executive compensation in future filings.
HCG completes ₹37.64 Cr divestment of BACC Health Care (Milann) to Inviga Healthcare Fund
Healthcare Global Enterprises (HCG) has completed the sale of its 99.999% stake in BACC Health Care Private Limited (Milann fertility centers) for a total consideration of ₹37.64 Cr. The company received an initial payment of ₹28.23 Cr on June 29, 2026, with the remaining balance structured as a non-conditional deferred payment due within 18 months. This divestment represents a strategic exit from the fertility segment to focus on core oncology operations. Given HCG's TTM revenue of ₹2,545 Cr, the deal size is relatively small at approximately 1.5% of annual turnover.
Confidence: HIGH
What changedHCG has officially exited its fertility business (BACC/Milann) by transferring the majority stake and receiving the first tranche of the sale proceeds.
Why it mattersThe move streamlines HCG's business model, allowing management to focus resources on its core oncology centers, which currently target a migration to higher revenue and margin buckets (>₹100 Mn monthly revenue per center).
Total Consideration: ₹37.64 CrInitial Payment Received: ₹28.23 CrDeal vs TTM Revenue: ~1.48%Deal vs Market Cap: ~0.26%Shares Transferred: 93,577
📅 Short termThe news is likely to be viewed neutrally by the market as the deal was previously announced and the financial magnitude is small relative to HCG's overall scale.
📈 Long termStrategically positive as it simplifies the corporate structure and focuses capital on the high-growth oncology segment where HCG maintains a leadership position in 16 cities.
⚠ Risk flags
- Deferred payment collection within the 18-month window
Key Highlights
Total consideration for the 100% stake sale is ₹37,64,44,788
Initial consideration of ₹28,23,33,591 received on June 29, 2026
Transfer of 93,577 shares (99.999%) completed; 1 share transfer in process
Deferred consideration is non-conditional and payable within 18 months of May 19, 2026
Divestment follows the Share Purchase Agreement (SPA) signed on May 19, 2026
👀 What to Watch
Investors should monitor the deployment of the ₹37.64 Cr proceeds, specifically whether it is used to reduce the company's ₹1,022 Cr debt or fund its ongoing oncology expansions in Vizag and Indore.
CDSCO Suspends HCG's KR Unit Ethics Committee for 24 Months Over Regulatory Lapses
The Central Drugs Standard Control Organization (CDSCO) has suspended the Ethics Committee of HCG's KR Unit in Bangalore from approving or overseeing new clinical trials for a period of 24 months. The order follows several alleged violations of the New Drugs and Clinical Trials Rules, 2019, including failures in reporting Serious Adverse Events (SAEs) and missing meeting minutes from 2022. While the suspension is specific to this unit's ethics committee, the company maintains that hospital operations and patient care remain unaffected. Management currently assesses no significant impact on financial operations.
Key Highlights
Ethics Committee of HCG Bangalore Institute of Oncology (KR Unit) suspended for 24 months starting June 2026.
Suspension prohibits the committee from approving or overseeing any new clinical trials or BA/BE studies.
Violations include failure to report SAEs within timelines and lack of 'no conflict of interest' disclosures from members.
Management states the order does not extend to other ethics committees, hospital operations, or patient care.
The company is currently examining the order and exploring available legal remedies.
👀 What to Watch
Investors should monitor if these regulatory lapses indicate broader compliance issues across other units, though the immediate financial impact appears limited to clinical research at one specific site.
HCG Promoter Confirms No New Encumbrances; 7.16 Crore Shares Released from Non-Disposal Undertaking
Hector Asia Holdings II Pte. Ltd., the promoter of HealthCare Global Enterprises Limited (HCG), has declared that no new encumbrances were created on its shareholding during the financial year ended March 31, 2026. The disclosure highlights the release of a non-disposal undertaking on 7,16,77,991 equity shares on September 17, 2025. This undertaking was originally linked to a facility agreement with HSBC dated February 23, 2025. The filing confirms compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations.
Key Highlights
Promoter Hector Asia Holdings II Pte. Ltd. declared zero new encumbrances for the fiscal year ended March 31, 2026.
A significant non-disposal undertaking involving 7,16,77,991 equity shares was released on September 17, 2025.
The released encumbrance was originally created on May 30, 2025, via a facility agreement with HSBC.
The declaration includes Persons Acting in Concert (PAC), specifically KIA EBT II Scheme 1.
Compliance filing submitted under Regulation 31(4) of SEBI (SAST) Regulations, 2011.
👀 What to Watch
Investors should take note of the release of the non-disposal undertaking as it indicates improved financial flexibility for the promoter. No immediate action is required as this is a routine annual compliance disclosure confirming a stable pledge status.
HCG Proposes New ESOP Scheme 2026 for 74.21 Lakh Shares and CEO Remuneration Revision
Healthcare Global Enterprises (HCG) has issued a postal ballot notice seeking shareholder approval for its new HCG Employee Stock Option Scheme 2026. The scheme proposes the issuance of up to 74,21,455 options, representing approximately 4.97% of the company's total share capital. Additionally, the company is seeking approval for the reappointment of Independent Director Rajiv Maliwal and a revision in the remuneration for CEO Dr. Manish Mattoo. The e-voting period for these resolutions is scheduled from June 9 to July 8, 2026.
Key Highlights
Proposed HCG ESOS 2026 involves 74,21,455 stock options, representing 4.97% of total share capital.
Approval sought for granting employee stock options exceeding 1% of issued share capital to a single employee.
Proposed revision in the remuneration structure for Dr. Manish Mattoo, Executive Director and CEO.
Resolution for the reappointment of Mr. Rajiv Maliwal as an Independent Director of the Company.
Remote e-voting period runs from June 09, 2026, to July 08, 2026, with results by July 10, 2026.
👀 What to Watch
Investors should evaluate the potential 4.97% equity dilution from the new ESOP scheme and assess if the CEO's revised remuneration is justified by recent financial performance.
HCG Reports 15% FY26 Revenue Growth and Divests Milann Fertility Business for INR 63 Crore
Healthcare Global Enterprises (HCG) delivered a strong FY26 performance with revenues reaching INR 2,545 crore, a 15% YoY increase. The company improved its operational efficiency, with adjusted EBITDA growing 19% to INR 471.1 crore and margins expanding to 18.5%. Strategically, HCG is divesting its Milann fertility business for an enterprise value of INR 63 crore to focus exclusively on its core oncology platform. A successful INR 425 crore rights issue has further strengthened the balance sheet, reducing net debt to 1.4x.
Key Highlights
FY26 revenue grew 15% YoY to INR 2,545 crore, supported by 12% volume growth and 3% ARPP improvement.
Adjusted EBITDA for FY26 rose 19% YoY to INR 471.1 crore, with Q4 margins expanding 90 bps to 19.2%.
Divested Milann fertility business for INR 63 crore enterprise value to prioritize oncology management bandwidth.
Completed a INR 425 crore rights issue, significantly deleveraging the company to a net debt/EBITDA of 1.4x.
Pre-tax ROCE improved to 14% driven by higher utilization and maturity of existing oncology centers.
👀 What to Watch
Investors should favor HCG's strategic shift toward a pure-play oncology model and its significantly improved balance sheet following the rights issue. Monitor the execution of brownfield expansions in Cuttack and Bangalore as key drivers for FY27 growth.
HCG Appoints Sanjeev Kumar as CFO; Dr. Manish Mattoo Steps Down as Interim CFO
Healthcare Global Enterprises Limited (HCG) has announced that Mr. Sanjeev Kumar has assumed the role of Chief Financial Officer (CFO) effective May 25, 2026. Consequently, Dr. Manish Mattoo, who is the Executive Director and CEO, has relinquished his additional charge as the Interim CFO. This transition follows the Board's approval on May 19, 2026, and marks the end of the interim arrangement. The move stabilizes the company's leadership structure by separating the CEO and CFO functions.
Key Highlights
Mr. Sanjeev Kumar appointed as permanent CFO and Key Managerial Personnel (KMP) effective May 25, 2026.
Dr. Manish Mattoo relinquishes Interim CFO role to focus on his primary duties as Executive Director and CEO.
The transition follows the Board of Directors' approval granted during the meeting held on May 19, 2026.
The appointment completes the permanent senior management team structure for the oncology-focused healthcare provider.
👀 What to Watch
This is a positive governance move as it separates the CEO and CFO functions, allowing for better management focus. Investors should monitor the new CFO's impact on the company's financial strategy and capital allocation in upcoming quarters.
HCG Confirms Zero Deviation in Utilization of ₹424.68 Crore Rights Issue Funds
Healthcare Global Enterprises Limited (HCG) has reported zero deviation in the utilization of ₹424.68 crore raised through its Rights Issue allotted on March 27, 2026. The company has earmarked ₹170 crore for debt repayment and ₹154.04 crore to acquire an additional 34% stake in its Vizag subsidiary. The Audit Committee has reviewed the statement, confirming that all funds are being directed toward the strategic objects outlined in the Letter of Offer. This transparency indicates disciplined capital management and adherence to stated growth and deleveraging plans.
Key Highlights
Total funds raised via Rights Issue: ₹424.68 Crores.
₹170 Crores allocated for the pre-payment or repayment of existing borrowings.
₹154.04 Crores designated for acquiring an additional 34% stake in Vizag Hospital and Cancer Research Center.
Zero deviation or variation reported from the objects stated in the Letter of Offer for the quarter ended March 31, 2026.
👀 What to Watch
Investors should view this as a positive sign of corporate governance and strategic capital allocation. Monitor future quarterly results for the impact of debt reduction on interest costs and the contribution from the increased stake in the Vizag subsidiary.
HCG to Divest Non-Core Fertility Business BACC for INR 37.64 Crore
Healthcare Global Enterprises (HCG) has entered into a Share Purchase Agreement to sell its 100% stake in BACC Health Care Private Limited to Inviga Healthcare Fund I for INR 37.64 crore. BACC, which operates in the fertility and reproductive healthcare space, is considered a non-core asset for HCG's oncology-focused business. The transaction is a related party deal as the buyer is controlled by HCG's Promoter and Chairman, Dr. B.S. Ajaikumar, but the company states it was conducted at arm's length with independent valuation. The sale is expected to conclude within 4-5 weeks, providing HCG with immediate liquidity and a sharper focus on its core operations.
Key Highlights
Divestment of 100% equity in BACC Health Care for a total consideration of INR 37.64 crore.
BACC contributed INR 60.45 crore (4.45%) to HCG's standalone revenue in FY 2025-26.
Upfront payment of INR 28.23 crore at closing, with a deferred payment of INR 9.41 crore within 18 months.
BACC's net worth stood at INR 17.53 crore, representing 1.09% of HCG's standalone net worth as of March 2026.
Strategic exit from non-core fertility business to focus resources on core oncology services.
👀 What to Watch
Investors should view this as a positive step toward streamlining the business and focusing on the high-growth oncology segment. Monitor how the company redeploys the sale proceeds into its core expansion plans.
HCG Q4FY26 Results: Adjusted PAT Surges 363% YoY; Revenue Up 11% to Rs. 6,523 Mn
Healthcare Global Enterprises (HCG) reported a strong performance for Q4FY26, with consolidated revenue growing 11% YoY to Rs. 6,523 Mn. The company's Adjusted EBITDA margin expanded by 91 bps to 19.2%, driven by better capacity utilization and cost management. For the full year FY26, revenue reached Rs. 25,454 Mn, a 15% increase, while Adjusted PAT grew 25% to Rs. 557 Mn. A significant highlight was the completion of a Rs. 4,250 Mn rights issue, strengthening the balance sheet for future expansion and technology upgrades.
Key Highlights
Q4FY26 Revenue grew 11% YoY to Rs. 6,523 Mn; FY26 Revenue up 15% to Rs. 25,454 Mn.
Adjusted EBITDA for Q4FY26 rose 17% YoY to Rs. 1,252 Mn with margins expanding to 19.2%.
Adjusted PAT for Q4FY26 saw a massive 363% YoY jump to Rs. 341 Mn.
Successfully raised Rs. 4,250 Mn through a rights issue to fund capacity expansion and technology.
Full-year FY26 Adjusted EBITDA increased 19% YoY to Rs. 4,711 Mn.
👀 What to Watch
Investors should view the margin expansion and the successful capital raise as positive indicators of operational efficiency and growth readiness. Monitor the utilization of rights issue proceeds for future capacity additions in the specialized oncology segment.
HCG FY26 Revenue Grows 15% to ₹25,454 Mn; Divests Milann Fertility Business for ₹632 Mn
Healthcare Global Enterprises (HCG) reported a strong financial performance for FY26, with consolidated revenue increasing 15% YoY to ₹25,454 Mn and Adjusted EBITDA rising 19% to ₹4,711 Mn. The company announced a strategic exit from its non-core fertility business, Milann, for an enterprise value of ₹632 Mn to focus exclusively on its oncology platform. Operational efficiency improved as Adjusted EBITDA margins expanded by 68 bps to 18.5%, supported by a 12% growth in patient volumes and a 3% rise in ARPP. The company also strengthened its clinical capabilities with the launch of a new facility in North Bangalore and the completion of a rights issue.
Key Highlights
FY26 Revenue increased 15% YoY to ₹25,454 Mn; Adjusted EBITDA grew 19% to ₹4,711 Mn.
Divestment of 100% stake in Milann fertility business for an enterprise value of ₹632 Mn to unlock value.
Adjusted EBITDA margin expanded to 18.5% in FY26 compared to 17.8% in FY25.
International business revenue surged 71% YoY in FY26, driven by radiation oncology and PET ramp-up.
Pre-tax ROCE improved to 14.0% in FY26, reflecting better asset utilization and disciplined capital allocation.
👀 What to Watch
Investors should look favorably on the divestment of the non-core fertility business as it allows management to focus on the high-growth oncology segment and improves capital efficiency. The steady margin expansion and volume growth suggest a strong competitive position in the specialized healthcare market.
HCG Appoints Sanjeev Kumar as CFO and Re-appoints Rajiv Maliwal as Independent Director
HealthCare Global Enterprises (HCG) has announced a significant leadership update, appointing Sanjeev Kumar as the new Chief Financial Officer effective May 25, 2026. Mr. Kumar brings over 30 years of experience, including a successful tenure as Group CFO at Medanta where he led their IPO. Additionally, the board has re-appointed Rajiv Maliwal as an Independent Director for a second five-year term and hired Ravi Gothwal to lead Investor Relations. These moves aim to strengthen the company's financial leadership and market engagement as the CEO steps down from his interim CFO role.
Key Highlights
Sanjeev Kumar appointed as CFO and KMP effective May 25, 2026, bringing 30+ years of experience from Medanta and Bharti Airtel.
Rajiv Maliwal re-appointed as Non-Executive Independent Director for a second 5-year term starting May 25, 2026.
Ravi Gothwal appointed as AVP – Investor Relations to enhance engagement with the investment community.
Dr. Manish Mattoo to cease holding the Interim CFO position upon Sanjeev Kumar's commencement.
Vijay S. Shanbhag re-appointed as Internal Auditor for a further 1-year term starting May 30, 2026.
👀 What to Watch
The appointment of a seasoned CFO with specific healthcare experience from a major peer like Medanta is a strong positive for HCG's financial strategy. Investors should view this as a strengthening of the management team and watch for improved investor communication through the new IR lead.
HCG to Divest BACC Health Care Stake for ₹37.64 Crore to Inviga Healthcare Fund
Healthcare Global Enterprises (HCG) has approved the sale of its entire equity stake in BACC Health Care Private Limited for a total consideration of ₹37.64 crore. BACC, which operates in the fertility and reproductive healthcare space, contributed approximately 4.45% (₹60.45 crore) to HCG's standalone revenue in FY 2025-26. The transaction is a related party deal as HCG's Chairman, Dr. B.S. Ajaikumar, sponsors the buyer fund, but the company stated it followed a competitive process and independent valuation. This divestment allows HCG to exit a non-core business and reinvest capital into its primary oncology services.
Key Highlights
Divestment of 100% equity in BACC Health Care for a total consideration of ₹37.64 crore
BACC contributed ₹60.45 crore to revenue and ₹17.53 crore to net worth in FY 2025-26
Payment includes ₹28.23 crore upfront at closing and ₹9.41 crore as deferred consideration within 18 months
Strategic exit from non-core fertility business to focus on core oncology and high-growth areas
Transaction is a Related Party Transaction involving the company's Promoter and Non-Executive Chairman
👀 What to Watch
Investors should monitor the reinvestment of these proceeds into the core oncology business, which typically offers better alignment with HCG's long-term strategy. While the related party nature of the deal requires oversight, the strategic rationale for exiting non-core assets is sound.
HCG to Divest Fertility Business for ₹37.64 Cr; Appoints Sanjeev Kumar as New CFO
Healthcare Global Enterprises (HCG) has announced the divestment of its entire stake in BACC Health Care Private Limited for INR 37.64 Crores to Inviga Healthcare Fund I. This strategic move allows the company to exit the non-core fertility business and focus resources on its primary oncology operations. Alongside the FY26 audited financial results, the board also approved the appointment of Sanjeev Kumar as the new Chief Financial Officer effective May 25, 2026. The statutory auditors have issued an unmodified opinion on the financial statements for the year ended March 31, 2026.
Key Highlights
Divestment of 100% equity in BACC Health Care for a total consideration of INR 37,64,44,788
Strategic exit from fertility and reproductive healthcare to focus on core oncology services
Appointment of Sanjeev Kumar as Chief Financial Officer (CFO) effective May 25, 2026
Re-appointment of Rajiv Maliwal as Independent Director for a second 5-year term
Statutory auditors B S R & Co. LLP issued a clean (unmodified) audit report for FY26
👀 What to Watch
Investors should view the exit from non-core, lower-margin fertility services as a positive step toward better capital allocation and operational focus on oncology. Monitor the transition under the new CFO and the impact of the divestment on consolidated margins.
HCG Launches 132-Bed Cancer Hospital in Hebbal with ₹129 Crore Investment
Healthcare Global Enterprises (HCG) has officially launched a new 132-bed comprehensive cancer hospital in Hebbal, North Bengaluru. The project involved a capital expenditure of approximately ₹129 Crores, financed through a combination of debt and internal accruals. This facility is strategically located to capture the underserved North Bengaluru market and features Karnataka’s first Elekta Unity MR-Linac technology. The expansion is expected to drive long-term revenue growth by strengthening HCG's dominant position in oncology care within its home market.
Key Highlights
Launch of a new 132-bed comprehensive cancer hospital in Hebbal, North Bengaluru
Total investment of approximately ₹129 Crores funded via debt and internal accruals
Introduction of Karnataka’s first Elekta Unity MR-Linac for high-precision radiation therapy
Full-spectrum oncology center providing diagnosis, treatment, and recovery support under one roof
Strategic expansion to bridge the gap in specialized cancer care for the North Bengaluru region
👀 What to Watch
Investors should monitor the hospital's occupancy ramp-up and its contribution to the company's consolidated EBITDA over the next 4-6 quarters. While the expansion is positive for long-term growth, watch for any short-term margin pressure due to initial operating costs and interest on debt.
HCG Q4FY26 Results: Adjusted PAT Surges 363% YoY; Revenue Up 11% to Rs 6,523 Mn
Healthcare Global Enterprises (HCG) reported a strong performance for FY26, with annual revenue growing 15% to Rs 25,454 Mn. The company's Q4FY26 adjusted PAT saw a significant jump of 363% YoY to Rs 341 Mn, driven by operational efficiencies and margin expansion. EBITDA margins improved to 19.2% in Q4, reflecting better capacity utilization across its oncology network. Additionally, the company successfully raised Rs 4,250 Mn through a rights issue to fund future growth and debt management.
Key Highlights
FY26 Revenue grew 15% YoY to Rs 25,454 Mn, while Q4 Revenue rose 11% to Rs 6,523 Mn.
Adjusted EBITDA for FY26 increased by 19% to Rs 4,711 Mn with margins expanding to 18.5%.
Q4 Adjusted PAT witnessed a massive 363% YoY growth, reaching Rs 341 Mn.
Successfully completed a Rs 4,250 Mn rights issue to strengthen the balance sheet and fund expansion.
Launched a new comprehensive cancer hospital in Hebbal, North Bengaluru, strengthening regional presence.
👀 What to Watch
Investors should view the margin expansion and strong PAT growth as positive indicators of HCG's specialized oncology model scaling effectively. The capital infusion from the rights issue provides a solid cushion for further network expansion and technology upgrades.
